CUMBERLAND, Md., July 08, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from deadly lung diseases...
RS BioTherapeutics announced today the launch of an SEC Regulation Crowdfunding (Reg CF) investment campaign through StartEngine.
RS BioTherapeutics is pleased to announce the addition of Jane Wright-Mitchell, Pharm.D., J.D. to the RS BioTherapeutics Business Advisory Board.
RS BioTherapeutics is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit
RS BioTherapeutics is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit
RS BioTherapeutics is pleased to announce the formation of its Therapeutic Expert Council (TEC).
RS BioTherapeutics Promotes Michelle L. Shuffett, MD to Chief Medical Officer
CUMBERLAND, Md., Aug. 29, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, a life sciences company developing life-changing medicines for the millions of people suffering from diseases characterized by...
CUMBERLAND, Md., June 05, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...
CUMBERLAND, Md., May 15, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...